Open Access. Powered by Scholars. Published by Universities.®

Dentistry Commons

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 6 of 6

Full-Text Articles in Dentistry

Contact Point, Arthur A. Dugoni School Of Dentistry Dec 2008

Contact Point, Arthur A. Dugoni School Of Dentistry

Contact Point

No abstract provided.


Enzastaurin, An Inhibitor Of Pkc Beta, Enhances Antiangiogenic Effects And Cytotoxicity Of Radiation Against Endothelial Cells., Aaron C. Spalding, Benjamin David Zeitlin, Kari Wilder-Romans, Mary Ellen Davis, Jacques E. Nör, Theodore S. Lawrence, Edgar Ben-Josef Dec 2008

Enzastaurin, An Inhibitor Of Pkc Beta, Enhances Antiangiogenic Effects And Cytotoxicity Of Radiation Against Endothelial Cells., Aaron C. Spalding, Benjamin David Zeitlin, Kari Wilder-Romans, Mary Ellen Davis, Jacques E. Nör, Theodore S. Lawrence, Edgar Ben-Josef

All Dugoni School of Dentistry Faculty Articles

PURPOSE: Angiogenesis plays an important role in pancreas cancer pathobiology. Pancreatic tumor cells secrete vascular endothelial growth factor (VEGF), activating endothelial cell protein kinase C beta (PKC beta) that phosphorylates GSK3 beta to suppress apoptosis and promote endothelial cell proliferation and microvessel formation. We used Enzastaurin (Enz) to test the hypothesis that inhibition of PKC beta results in radiosensitization of endothelial cells in culture and in vivo. MATERIALS/METHODS: We measured PKC beta phosphorylation, VEGF pathway signaling, colony formation, and capillary sprout formation in primary human dermal microvessel endothelial cells (HDMECs) after Enz or radiation (RT) treatment. Microvessel density and tumor …


Expanding Circle Of Inhibition: Small-Molecule Inhibitors Of Bcl-2 Asanticancer Cell And Antiangiogenic Agents, Benjamin David Zeitlin, Isaac J. Zeitlin, Jacques E. Nör Sep 2008

Expanding Circle Of Inhibition: Small-Molecule Inhibitors Of Bcl-2 Asanticancer Cell And Antiangiogenic Agents, Benjamin David Zeitlin, Isaac J. Zeitlin, Jacques E. Nör

All Dugoni School of Dentistry Faculty Articles

The specific targeting of diseases, particularly cancer, is a primary aim in drug development, as specificity reduces unwelcome effects on healthy tissue and increases drug efficacy at the target site. Drug specificity can be increased by improving the delivery system or by selecting drugs with affinity for a molecular ligand specific to the disease state. The role of the prosurvival Bcl-2 protein in maintaining the normal balance between apoptosis and cellular survival has been recognized for more than a decade. Bcl-2 is vital during development, much less so in adults. It has also been noted that some cancers evade apoptosis …


Contact Point, Arthur A. Dugoni School Of Dentistry Aug 2008

Contact Point, Arthur A. Dugoni School Of Dentistry

Contact Point

No abstract provided.


Contact Point, Arthur A. Dugoni School Of Dentistry Jun 2008

Contact Point, Arthur A. Dugoni School Of Dentistry

Contact Point

No abstract provided.


10th Annual Pacific Research Day Abstracts, University Of The Pacific May 2008

10th Annual Pacific Research Day Abstracts, University Of The Pacific

Excellence Day

No abstract provided.